Success Stories: Research Fellow in the Field of Pulmonary Medicine in Missouri Received an EB-1A Approval
We Received an EB-1A Approval on July 21st, 2014 for aResearch Fellowin the Field of Pulmonary Medicine (Approval Notice)
General Field: Pulmonary Medicine
Position at the Time of Case Filing: Research Fellow
Country of Origin: India
Service Center: Nebraska Service Center (NSC)
State of Residence at the Time of Filing: Missouri
Approval Notice Date: July 21, 2014
Processing Time: 5 months and 9 days
Case Summary:
For this EB-1A case, we had the privilege of working with aResearch Fellow, who has made substantial contributions and garnered international acclaim in the field of Pulmonary Medicine. In his research endeavors, our client has studied the pathogenesis of obstructive airway diseases, such as severe asthma, chronic obstructive pulmonary disease (COPD), and bronchiolitis obliterans, the leading cause of transplanted lung failure. His work has led to seminal findings relating to the immunopathology of sepsis, which is the leading cause of death in many hospitals. The originality of our client’s work has culminated in the authorship of several international conference proceedings, 3 book chapters, and 12 peer-reviewed scientific manuscripts that were published in the top journals of his field. At the time of filing his case, his publications had been cited 64 times by researchers worldwide, demonstrating the global scientific community’s heavy reliance upon his work. Furthermore, his work has been presented and discussed at internationally renowned conferences. The major significance of his work was endorsed by an independent recommender, who stated, “The lack of effective treatments for severe asthma is an internationally shared concern among pulmonologists. Estimates show roughly 300 million people around the world have asthma and 5-10% of these patients have refractory severe asthma. To serve this community, we must better understand the biological processes responsible for worsening this disease. [Client’s] work has taken this effort to a new, more hopeful level. He has focused on addressing the dearth of knowledge that underlies why many patients with asthma are refractory to the current available treatments. Research of this nature has provided pulmonologists with a foundation for understanding how morphometric changes in wall area thickness can promote a continued understanding of the pathogenesis of severe asthma.” Additionally, our client has been invited to judge the work of his colleagues and other forerunners in his field, and he has served as a manuscript reviewer for 7 internationally circulated journals. With the extensive and thorough documentation that we provided, we exhibited the immeasurable value of our client’s contributions to the current state of the healthcare system. In demonstrating the extraordinary ability of our client and international acclaim for his research, we were able to prove that he has risen to the very top of his field of endeavor. We were met with success when his EB-1Apetition was approved in 5 months and 9 days.